ANAB * Stock Overview
A clinical-stage biotechnology company, focuses in delivering immunology therapeutics.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
AnaptysBio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$580.00 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | -0.14 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -47.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| ANAB * | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | 0% | 0% | 0% |
Return vs Industry: ANAB * exceeded the MX Biotechs industry which returned -6% over the past year.
Return vs Market: ANAB * underperformed the MX Market which returned 3.7% over the past year.
Price Volatility
| ANAB * volatility | |
|---|---|
| ANAB * Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: ANAB * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ANAB *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 96 | Dan Faga | www.anaptysbio.com |
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 trial for the treatment of generalized pustular psoriasis; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations.
AnaptysBio, Inc. Fundamentals Summary
| ANAB * fundamental statistics | |
|---|---|
| Market cap | Mex$8.43b |
| Earnings (TTM) | -Mex$2.38b |
| Revenue (TTM) | Mex$185.72m |
45.4x
P/S Ratio-3.5x
P/E RatioIs ANAB * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANAB * income statement (TTM) | |
|---|---|
| Revenue | US$10.69m |
| Cost of Revenue | US$101.24m |
| Gross Profit | -US$90.55m |
| Other Expenses | US$46.18m |
| Earnings | -US$136.72m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.16 |
| Gross Margin | -846.96% |
| Net Profit Margin | -1,278.87% |
| Debt/Equity Ratio | 0% |
How did ANAB * perform over the long term?
See historical performance and comparison